Inlyta and Xalkori.

Total Oncology revenues from emerging markets were $363 million in 2013.

Consumer Healthcare Revenues increased 4% to $3,342 million in 2013, compared to $3,212 million in 2012, due to strong growth for Centrum as a result of several recent product launches; increased promotional activities for various products in key markets; and the growth of Emergen-C in the U.S. due to expanded distribution and promotional activities, partially offset by a decline in sales of pain management products (mostly in the U.S.).

Total Consumer Healthcare revenues from emerging markets were $925 million in 2013.

• Cost of sales increased 1% to $1,843 million in 2013, compared to $1,822 million in 2012, primarily due to increased sales volumes.

• Research and development expenses decreased 23% in 2013, compared to 2012, primarily driven by the non-recurrence of a $250 million payment to AstraZeneca in 2012 to obtain the exclusive, global, OTC rights to Nexium.

Global Established Pharmaceutical Operating Segment

2014 vs. 2013:

             •

Revenues decreased 9%, to $25,149 million in 2014, compared to $27,619 million in 2013, including a decrease in operational revenues of 7% in 2014, primarily due to:

the loss of exclusivity and subsequent launch of multi-source generic competition for Detrol LA in the U.S. in January 2014, Celebrex in the U.S. in December 2014 and developed Europe in November 2014, Viagra in most major European markets in June 2013 as well as Aricept in Canada in December 2013 (aggregate decline of approximately $826 million in 2014);

the expiration or near-term expiration of the co-promotion collaboration for Spiriva in most countries, which has resulted in a decline in Pfizer’s share of Spiriva revenues (approximately $490 million in 2014);

a decline in branded Lipitor revenues in the U.S. and most other developed markets as a result of continued generic competition (approximately $388 million in 2014);

the operational decline of certain products, including Effexor, Norvasc, atorvastatin, Zosyn/Tazocin, Metaxalone, Ziprasidone and Tygacil (approximately $428 million in 2014);

an operational decline due to loss of exclusivity for certain other products in developed markets (approximately $170 million in 2014); and

a decline in Aricept, not including Canada, revenues primarily due to the termination of the co-promotion agreement in Japan in December 2012 (approximately $75 million in 2014),

partially offset by:

the operational growth of Lipitor in China (approximately $164 million in 2014);

the strong operational performance of Lyrica in Europe (growth of approximately $144 million in 2014); and

the contribution from the collaboration with Mylan Inc. to market generic drugs in Japan (approximately $37 million in 2014). Foreign exchange had an unfavorable impact of 2% on GEP revenues in 2014.

Total GEP revenues from emerging markets were $7.5 billion in 2014.

• Cost of sales as a percentage of Revenues increased 1% in 2014 compared to 2013, primarily due to the impact of losses of exclusivity and an unfavorable change in product mix. The 3% decrease in Cost of sales is primarily driven by favorable